160132-91-2

Basic information

• Product Name: 4-Methyl-4-phenylpiperidine
• Synonyms: 4-Methyl-4-phenylpiperidine
• CAS NO: 160132-91-2
• Molecular Formula: C₁₂H₁₇N
• Molecular Weight: 175.27008
• Mol File: 160132-91-2.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-Methyl-4-phenylpiperidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Methyl-4-phenylpiperidine(160132-91-2)
• EPA Substance Registry System: 4-Methyl-4-phenylpiperidine(160132-91-2)

Safety Data

• Hazardous Substances Data: 160132-91-2(Hazardous Substances Data)

Usage

General Description

4-Methyl-4-phenylpiperidine, also known as MPTP, is a synthetic opioid that acts on the central nervous system to produce analgesic effects. It is a potent and selective agonist for the mu-opioid receptor, making it a highly effective painkiller. MPTP is also known to have a high potential for abuse and dependence, and is listed as a Schedule II controlled substance in the United States. Due to its high potency and potential for abuse, MPTP is closely regulated and has limited medical uses. It is primarily used as a research chemical and is not approved for use in clinical settings. MPTP is considered to be a dangerous substance due to its potential for abuse and overdose, and its use is strictly controlled.

Upstream product

• 3970-66-9 1-benzyl-4-methyl-piperidin-4-ol 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 160133-26-6 1-benzyl-4-methyl-4-phenyl piperidine 

Downstream Products

• 166809-69-4 1-(3-amino-propyl)-4-methyl-4-phenyl-piperidine 

Relevant articles and documents

Structural changes of benzylether derivatives of vesamicol and their influence on the binding selectivity to the vesicular acetylcholine transporter

18F labelled vesamicol analogues, which bind to the vesicular acetylcholine transporter (VAChT) in central cholinergic nerve terminals, are expected to be potential radioligands for the visualisation of cholinergic transmission deficits via pos

5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines

This invention is directed to dihydropyrimidine compounds of the following formula: which are selective antagonists for human α1Areceptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where antagonism of the α1Areceptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

Design and synthesis of novel α1a adrenoceptor-selective dihydropyridine antagonists for the treatment of benign prostatic hyperplasia

We report the synthesis and evaluation of novel ttia adrenoceptor subtype-selective antagonists. Systematic modification of the lipophilic 4,4-diphenylpiperidinyl moiety of the dihydropyridine derivatives 1 and 2 provided several highly selective and potent α1a antagonists. From this series, we identified the 4-(methoxycarbonyl)-4-phenylpiperidine analogue SNAP 5540 (-) [(-)-63] for further characterization. When examined in an isolated human prostate tissue assay, this compound was found to have a Ki of 2.8 nM, in agreement with the cloned human receptor binding data (Ki = 2.42 nM). Further evaluation of the compound in isolated dog prostate tissue showed a Ki of 3.6 nM and confirmed it to be a potent antagonist (Kb = 1.6 nM). In vivo, this compound effectively blocked the phenylephrine-stimulated increase in intraurethral pressure (IUP) in mongrel dogs, at doses which did not significantly affect the arterial pressure (diastolic blood pressure, DBF), with a DBF Kb/IUP-Kb ratio of 16. In addition, (-)-63 also showed greater than 40 000-fold selectivity over the rat L-type calcium channel and 200-fold selectivity over several G protein-coupled receptors, including histamine and serotonin subtypes. These findings prove that aia adrenoceptor-subtype selective antagonists such as (-)-63 may be developed as uroselective agents for an improved treatment of BPH over nonselective 0.1 antagonists such as prazosin and terazosin, with fewer side effects.